JPH06505482A - 感染治療および叢制御の方法および組成物 - Google Patents
感染治療および叢制御の方法および組成物Info
- Publication number
- JPH06505482A JPH06505482A JP4507310A JP50731092A JPH06505482A JP H06505482 A JPH06505482 A JP H06505482A JP 4507310 A JP4507310 A JP 4507310A JP 50731092 A JP50731092 A JP 50731092A JP H06505482 A JPH06505482 A JP H06505482A
- Authority
- JP
- Japan
- Prior art keywords
- mpo
- pmol
- peroxide
- haloperoxidase
- per
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 108
- 239000000203 mixture Substances 0.000 title claims description 76
- 208000015181 infectious disease Diseases 0.000 title claims description 34
- 238000011282 treatment Methods 0.000 title claims description 16
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 156
- 244000005700 microbiome Species 0.000 claims description 148
- 150000004820 halides Chemical class 0.000 claims description 64
- 150000002978 peroxides Chemical class 0.000 claims description 64
- 239000003755 preservative agent Substances 0.000 claims description 51
- 108010035722 Chloride peroxidase Proteins 0.000 claims description 43
- 108010023244 Lactoperoxidase Proteins 0.000 claims description 42
- 102000045576 Lactoperoxidases Human genes 0.000 claims description 42
- 229940057428 lactoperoxidase Drugs 0.000 claims description 42
- 230000006378 damage Effects 0.000 claims description 41
- 230000002335 preservative effect Effects 0.000 claims description 40
- 239000000126 substance Substances 0.000 claims description 34
- 239000007788 liquid Substances 0.000 claims description 30
- 102000003992 Peroxidases Human genes 0.000 claims description 29
- 102000004316 Oxidoreductases Human genes 0.000 claims description 26
- 108090000854 Oxidoreductases Proteins 0.000 claims description 26
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 26
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 24
- 230000002327 eosinophilic effect Effects 0.000 claims description 22
- 102000004190 Enzymes Human genes 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 19
- 229940088598 enzyme Drugs 0.000 claims description 19
- 244000000010 microbial pathogen Species 0.000 claims description 19
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 18
- 241000282414 Homo sapiens Species 0.000 claims description 18
- 230000012010 growth Effects 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 230000001717 pathogenic effect Effects 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 11
- 239000007800 oxidant agent Substances 0.000 claims description 11
- 244000052769 pathogen Species 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 238000007323 disproportionation reaction Methods 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- 150000001805 chlorine compounds Chemical group 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 102000003896 Myeloperoxidases Human genes 0.000 claims 16
- 108090000235 Myeloperoxidases Proteins 0.000 claims 16
- 208000024891 symptom Diseases 0.000 claims 12
- 239000006193 liquid solution Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000037114 Symptom Flare Up Diseases 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 description 109
- 230000002147 killing effect Effects 0.000 description 92
- 241000894006 Bacteria Species 0.000 description 80
- 238000006243 chemical reaction Methods 0.000 description 71
- 230000003641 microbiacidal effect Effects 0.000 description 56
- 241000191967 Staphylococcus aureus Species 0.000 description 55
- 230000000694 effects Effects 0.000 description 50
- 241000194017 Streptococcus Species 0.000 description 46
- 230000000813 microbial effect Effects 0.000 description 46
- 241000588724 Escherichia coli Species 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 32
- 239000000725 suspension Substances 0.000 description 32
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 31
- 230000001419 dependent effect Effects 0.000 description 31
- 241000222122 Candida albicans Species 0.000 description 28
- 229940095731 candida albicans Drugs 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 108010015776 Glucose oxidase Proteins 0.000 description 25
- 239000004366 Glucose oxidase Substances 0.000 description 25
- 229940116332 glucose oxidase Drugs 0.000 description 25
- 235000019420 glucose oxidase Nutrition 0.000 description 25
- 238000010790 dilution Methods 0.000 description 22
- 239000012895 dilution Substances 0.000 description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 21
- 239000000463 material Substances 0.000 description 21
- 230000003647 oxidation Effects 0.000 description 19
- 238000007254 oxidation reaction Methods 0.000 description 19
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 18
- 239000008103 glucose Substances 0.000 description 17
- 230000005764 inhibitory process Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 15
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 14
- 230000001580 bacterial effect Effects 0.000 description 14
- 239000000975 dye Substances 0.000 description 14
- 239000008188 pellet Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 13
- 230000009471 action Effects 0.000 description 13
- 239000003242 anti bacterial agent Substances 0.000 description 13
- 230000000844 anti-bacterial effect Effects 0.000 description 13
- 229940088710 antibiotic agent Drugs 0.000 description 13
- 239000000460 chlorine Substances 0.000 description 13
- 229910052801 chlorine Inorganic materials 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 239000006228 supernatant Substances 0.000 description 13
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 241000233866 Fungi Species 0.000 description 11
- 238000001228 spectrum Methods 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 10
- 230000008033 biological extinction Effects 0.000 description 10
- 230000002949 hemolytic effect Effects 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 229910001868 water Inorganic materials 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 230000002421 anti-septic effect Effects 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical compound [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 230000001590 oxidative effect Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000001554 Hemoglobins Human genes 0.000 description 7
- 108010054147 Hemoglobins Proteins 0.000 description 7
- 241001312524 Streptococcus viridans Species 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000003197 catalytic effect Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 238000006213 oxygenation reaction Methods 0.000 description 7
- 230000009257 reactivity Effects 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 206010018910 Haemolysis Diseases 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000008588 hemolysis Effects 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 210000005253 yeast cell Anatomy 0.000 description 6
- 102000016938 Catalase Human genes 0.000 description 5
- 108010053835 Catalase Proteins 0.000 description 5
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical class ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 5
- 241000191940 Staphylococcus Species 0.000 description 5
- 241000193996 Streptococcus pyogenes Species 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000002860 competitive effect Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 235000013350 formula milk Nutrition 0.000 description 5
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 208000012868 Overgrowth Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- -1 chloramines ion Chemical class 0.000 description 4
- 239000000645 desinfectant Substances 0.000 description 4
- 229910001882 dioxygen Inorganic materials 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002538 fungal effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000013390 scatchard method Methods 0.000 description 4
- 238000004611 spectroscopical analysis Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 241001478240 Coccus Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000295644 Staphylococcaceae Species 0.000 description 3
- 206010042566 Superinfection Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 230000005283 ground state Effects 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000012886 linear function Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- 239000000052 vinegar Substances 0.000 description 3
- 235000021419 vinegar Nutrition 0.000 description 3
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 2
- 201000007336 Cryptococcosis Diseases 0.000 description 2
- 241000221204 Cryptococcus neoformans Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000194022 Streptococcus sp. Species 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- 150000001649 bromium compounds Chemical group 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005281 excited state Effects 0.000 description 2
- 208000015756 familial Alzheimer disease Diseases 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 238000005558 fluorometry Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- CUILPNURFADTPE-UHFFFAOYSA-N hypobromous acid Chemical compound BrO CUILPNURFADTPE-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000037125 natural defense Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000003300 oropharynx Anatomy 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000001706 oxygenating effect Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000010517 secondary reaction Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 235000021081 unsaturated fats Nutrition 0.000 description 2
- 230000036325 urinary excretion Effects 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 241000243329 Coleps Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010059284 Epidermal necrosis Diseases 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000186610 Lactobacillus sp. Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 101150083961 MPO1 gene Proteins 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000223785 Paramecium Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 241000287462 Phalacrocorax carbo Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241001134658 Streptococcus mitis Species 0.000 description 1
- 206010042276 Subacute endocarditis Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- ZJRXSAYFZMGQFP-UHFFFAOYSA-N barium peroxide Chemical compound [Ba+2].[O-][O-] ZJRXSAYFZMGQFP-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960001506 brilliant green Drugs 0.000 description 1
- HXCILVUBKWANLN-UHFFFAOYSA-N brilliant green cation Chemical compound C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 HXCILVUBKWANLN-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229910001919 chlorite Inorganic materials 0.000 description 1
- 229910052619 chlorite group Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000010454 developmental mechanism Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001914 gastric parietal cell Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001831 immunophysiological effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- VCLYJTVFGQHHHD-UHFFFAOYSA-N methyl-(4-nitrophenoxy)-phenoxy-sulfanylidene-$l^{5}-phosphane Chemical compound C=1C=C([N+]([O-])=O)C=CC=1OP(=S)(C)OC1=CC=CC=C1 VCLYJTVFGQHHHD-UHFFFAOYSA-N 0.000 description 1
- 230000007269 microbial metabolism Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000004767 nitrides Chemical class 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 206010033072 otitis externa Diseases 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000007539 photo-oxidation reaction Methods 0.000 description 1
- 238000007124 photooxygenation reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000007651 self-proliferation Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000004894 snout Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 208000008467 subacute bacterial endocarditis Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 208000010484 vulvovaginitis Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/50—Isolated enzymes; Isolated proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/082—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances in combination with specific enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/12—Non-macromolecular oxygen-containing compounds, e.g. hydrogen peroxide or ozone
- A61L12/124—Hydrogen peroxide; Peroxy compounds
- A61L12/126—Hydrogen peroxide; Peroxy compounds neutralised with catalase or peroxidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/38—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L2300/254—Enzymes, proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Agronomy & Crop Science (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims (58)
- 1.治療を必要とするヒトまたは動物宿主の治療方法であって、該方法は過酸化 物およびハライドの存在下病原性徴生物の増殖を阻止するのに治療的に有効であ るが対象の正常な細胞を顕著に損傷するには無効である量のハロパーオキシダー ゼを上記宿主に投与することを含む方法。
- 2.上記宿主に投与するハロパーオキシダーゼの量が該宿主の正常叢を消失させ るには無効である請求項1に記載の方法。
- 3.上記宿主の正常叢の再コロニー形成を促進するのに有効な量の正常叢を該宿 主に投与することから更になる請求項1に記載の方法。
- 4.ハロパーオキシダーゼがミエロパーオキシダーゼ(MPO)、好酸性パーオ キシダーゼ(EPO)、ラクトパーオキシダーゼ(LPO)、クロロパーオキシ ダーゼ(CPO)および病原性徴生物に選択的に結合し、ハライドを酸化しそし て過酸化物の不均化を高めて一重項分子酸素を形成し得る上記の誘導体からなる 群から選択される請求項1に記載の方法。
- 5.ハロパーオキシダーゼがMPOまたは病原性徴生物に選択的に結合し得るC PO誘導体でありそしてハライドが塩化物または臭化物である請求項4に記載の 方法。
- 6.ハライドが塩化物でありそして病原性徴生物部位における塩化物対過酸化物 の比を約1から40,000の範囲に維持することから更になる請求項5に記載 の方法。
- 7.塩化物対過酸化物の比が約200から約40,000の範囲に維持される請 求項6に記載の方法。
- 8.ハロパーオキシダーゼがEPO、LPOまたは病原性徴生物に選択的に結合 し得るLPO誘導体でありそしてハライドが臭化物である請求項4に記載の方法 。
- 9.病原性徴生物部位における臭化物対過酸化物の比を約0.1から約4,00 0の範囲に維持することから更になる請求項8に記載の方法。
- 10.臭化物対過酸化物の比が約1から約1,000の範囲に維持される請求項 9に記載の方法。
- 11.ハロパーオキシダーゼが上記対象に液体溶液の形態で投与されそして該溶 液1ml当たり約0.01pmolから約500pmolのハロパーオキシダー ゼが該対象に投与される請求項1に記載の方法。
- 12.上記溶液1ml当たり約0.1pmolから約50pmolのハロパーオ キシダーゼが上記対象に投与される請求項11に記載の方法。
- 13.上記溶液1ml当たり約0.5pmolから約5pmolのハロパーオキ シダーゼが上記対象に投与される請求項12に記載の方法。
- 14.過酸化物または上記対象に投与されるとき過酸化物を生成し得る物質を該 対象に投与することから更になる請求項1に記載の方法。
- 15.病原性微生物の感染をわずらっているヒトまたは動物宿主を治療する方法 であって、該方法は過酸化物およびハライドの存在下防腐剤的に有効であるが該 宿主の正常な細胞を顕著に損傷するには無効である量のハロパーオキシダーゼを 該宿主に投与することを含む方法。
- 16.上記宿主に投与されるハロパーオキシダーゼの量が該宿主の正常叢を消失 させるには無効である請求項15に記載の方法。
- 17.上記宿主の正常叢の再コロニー形成を促進するのに有効な量の正常叢を該 宿主に投与することから更になる請求項15に記載の方法。
- 18.ハロパーオキシダーゼがミエロパーオキシダーゼ(MPO)、好酸性パー オキシダーゼ(EPO)、ラクトパーオキシダーゼ(LPO)、クロロパーオキ シダーゼ(CPO)および病原性徴生物に選択的に結合し、ハライドを酸化しそ して過酸化物の不均化を高めて一重項分子酸素を形成し得る上記の誘導体からな る群から選択される請求項15に記載の方法。
- 19.ハロパーオキシダーゼがMPOまたは病原性微生物に選択的に結合し得る CPO誘導体でありそしてハライドが塩化物または臭化物である請求項18に記 載の方法。
- 20.ハライドが塩化物でありそして感染部位における塩化物対過酸化物の比を 約1から40,000の範囲に維持することから更になる請求項19に記載の方 法。
- 21.塩化物対過酸化物の比が約200から約40,000の範囲に維持される 請求項20に記載の方法。
- 22.ハロパーオキシダーゼがEPO、LPOまたは病原性微生物に選択的に結 合し得るLPO誘導体でありそしてハライドが臭化物である請求項18に記載の 方法。
- 23.感染部位における臭化物対過酸化物の比を約0.1から約4,000の範 囲に維持することから更になる請求項22に記載の方法。
- 24.臭化物対過酸化物の比が約1から約1,000の範囲に維持される請求項 23に記載の方法。
- 25.ハロパーオキシダーゼが上記宿主に液体溶液の形態で投与されそして該溶 液1ml当たり約0.01pmolから約500pmolのハロパーオキシダー ゼが該宿主に投与される請求項15に記載の方法。
- 26.上記溶液1ml当たり約0.lpmolから約50pmolのハロパーオ キシダーゼが上記宿主に投与される請求項25に記載の方法。
- 27.上記溶液1ml当たり約0.5pmolから約5pmolのハロパーオキ シダーゼが該宿主に投与される請求項26に記載の方法。
- 28.過酸化物または過酸化物を生成し得る物質を上記宿主に投与することから 更になる請求項15に記載の方法。
- 29.第1の徴生物が第2の徴生物より結合ハロパーオキシダーゼ対遊離ハロパ ーオキシダーゼ比が大きい第1の徴生物と第2の徴生物からなる媒体中で第1の 徴生物の増殖を選択的に阻止する方法であって、該方法は過酸化物およびハライ ドと接触するとき第1の徴生物に選択的に結合しそして該微生物の増殖を阻止す るのに有効であるが第2の徴生物を消失させるには無効である量のハロパーオキ シダーゼを上記媒体に導入するを含む方法。
- 30.ハロパーオキシダーゼがミエロパーオキシダーゼ(MPO)、好酸性パー オキシダーゼ(EPO)、ラクトパーオキシダーゼ(LPO)、クロロパーオキ シダーゼ(CPO)および第1の徴生物に選択的に結合し、ハライドを酸化しそ して過酸化物の不均化を高めて一重項分子酸素を形成し得る上記の誘導体からな る群から選択される請求項29に記載の方法。
- 31.ハロパーオキシダーゼがMPOまたは第1の徴生物に選択的に結合し得る CPO誘導体でありそしてハライドが塩化物または臭化物である請求項30に記 載の方法。
- 32.ハライドが塩化物でありそして治療部位における塩化物対過酸化物の比を 約1から40,000の範囲に維持することから更になる請求項31に記載の方 法。
- 33.塩化物対過酸化物の比が約200から約40.000の範囲に維持される 請求項32に記載の方法。
- 34.ハロパーオキシダーゼがEPO、LPOまたは第1の徴生物に選択的に結 合し得るLPO誘導体でありそしてハライドが臭化物である請求項30に記載の 方法。
- 35.治療部位における臭化物対過酸化物の比を約0.1から約4.000の範 囲に維持することから更になる請求項34に記載の方法。
- 36.臭化物対過酸化物の比が約1から約1.000の範囲に維持される請求項 35に記載の方法。
- 37.上記宿主が、液体溶液1ml当たり約0.01pmolから約500pm olのハロパーオキシダーゼからなる液体溶液と接触させられる請求項29に記 載の方法。
- 38.上記液体溶液が1ml当たり約0.1pmolから約50pmolのハロ パーオキシダーゼを含む請求項37に記載の方法。
- 39.上記液体溶液が1ml当たり約0.5pmolから約5pmolのハロパ ーオキシダーゼを含む請求項38に記載の方法。
- 40.上記第1の徴生物に過酸化物または過酸化物を生成し得る物質を接触させ ることから更になる請求項29に記載の方法。
- 41.過酸化物およびハライドの存在下ヒトまたは動物宿主に投与するとき、該 宿主中の病原性徴生物に選択的に結合しそして該徴生物の増殖を阻止するのに有 効な量のハロパーオキシダーゼ並びに製薬的に受容可能な担体を含む製薬組成物 。
- 42.ハロパーオキシダーゼがミエロパーオキシダーゼ(MPO)、好酸性パー オキシダーゼ(EPO)、ラクトパーオキシダーゼ(LPO)、クロロパーオキ シダーゼ(CPO)および病原性徴生物に選択的に結合し、ハライドを酸化しそ して過酸化物の不均化を高めて一重項分子酸素を形成し得る上記の誘導体からな る群から選択される請求項41に記載の組成物。
- 43.ハロパーオキシダーゼがMPOまたは病原性徴生物に選択的に結合し、塩 化物または臭化物を酸化しそして過酸化物の不均化を高めて一重項分子酸素を形 成し得るCPO誘導体である請求項42に記載の組成物。
- 44.製薬的に受容可能な液体担体中1ml当たり約0.01pmolから約5 00pmolのミエロパーオキシダーゼを含む請求項43に記載の組成物。
- 45.製薬的に受容可能な液体担体中1ml当たり約0.1pmo1から約50 pmolのミエロパーオキシダーゼからなる請求項44に記載の組成物。
- 46.製薬的に受容可能な液体担体中1ml当たり約0.5pmo1から約5p molのミエロパーオキシダーゼからなる請求項45に記載の組成物。
- 47.ハロパーオキシダーゼがEPO、LPOまたは病原性微生物に選択的に結 合し、臭化物を酸化しそして臭化物の存在下過酸化物の不均化を高めて一重項分 子酸素を形成し得るLPO誘導体である請求項42に記載の組成物。
- 48.製薬的に受容可能な液体担体中1ml当たり約0.01pmolから約5 00pmolの好酸性パーオキシダーゼを含む請求項47に記載の組成物。
- 49.製薬的に受容可能な液体坦体中1ml当たり約0.1pmolから約50 pmolの好酸性パーオキシダーゼを含む請求項48に記載の組成物。
- 50.製薬的に受容可能な液体担体中1ml当たり約0.5pmolから約5p molの好酸性パーオキシダーゼを含む請求項49に記載の組成物。
- 51.製薬的に受容可能な液体担体中約10nmolから約10μmolの臭化 物から更になる請求項47に記載の組成物。
- 52.1ml当たり約100nmolから約1μmolの臭化物を含む請求項5 1に記載の組成物。
- 53.過酸化水素から更になる請求項41に記載の組成物。
- 54.製薬的に受容可能な液体担体中1ml当たり約1nmolから約10μm olの過酸化水素を含む請求項53に記載の組成物。
- 55.製薬的に受容可能な液体担体中1ml当たり約5nmolから約5μmo lの過酸化水素を含む請求項54に記載の組成物。
- 56.製薬的に受容可能な液体担体中1ml当たり約10nmolから約1μm olの過酸化水素を含む請求項55に記載の組成物。
- 57.ヒトまたは動物宿主に投与するとき、1分当たり1ml当たり約1pmo lから約100nmolの過酸化物を発生するのに有効な過酸化物生成オキシダ ーゼから更になる請求項41に記載の組成物。
- 58.請求項41の製薬組成物を含む創傷用包帯。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66099491A | 1991-02-21 | 1991-02-21 | |
US660,994 | 1991-02-21 | ||
PCT/US1992/001237 WO1992014484A1 (en) | 1991-02-21 | 1992-02-14 | Methods and compositions for the treatment of infection and control of flora |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004167857A Division JP2004300157A (ja) | 1991-02-21 | 2004-06-04 | 感染治療および叢制御の方法および組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06505482A true JPH06505482A (ja) | 1994-06-23 |
JP4063317B2 JP4063317B2 (ja) | 2008-03-19 |
Family
ID=24651753
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50731092A Expired - Lifetime JP4063317B2 (ja) | 1991-02-21 | 1992-02-14 | 感染治療および叢制御の方法および組成物 |
JP2004167857A Withdrawn JP2004300157A (ja) | 1991-02-21 | 2004-06-04 | 感染治療および叢制御の方法および組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004167857A Withdrawn JP2004300157A (ja) | 1991-02-21 | 2004-06-04 | 感染治療および叢制御の方法および組成物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US6294168B1 (ja) |
EP (2) | EP0923939B1 (ja) |
JP (2) | JP4063317B2 (ja) |
KR (1) | KR930703012A (ja) |
AT (2) | ATE365048T1 (ja) |
AU (1) | AU663869B2 (ja) |
CA (1) | CA2061601C (ja) |
DE (2) | DE69229512T2 (ja) |
IE (1) | IE920514A1 (ja) |
IL (1) | IL100997A (ja) |
WO (1) | WO1992014484A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004537374A (ja) * | 2001-08-08 | 2004-12-16 | ノバルティス アクチエンゲゼルシャフト | コンタクトレンズ向けの消毒および洗浄システム |
JP2007051153A (ja) * | 1995-06-01 | 2007-03-01 | Exoxemis Inc | 殺菌または滅菌のための酸素による活性化可能な処方物 |
JP2011519954A (ja) * | 2008-05-09 | 2011-07-14 | エクソゼミス,インコーポレイテッド | ミエロペルオキシダーゼの抗菌活性を増強するための組成物、およびそれらの使用方法 |
JP2014520853A (ja) * | 2011-07-11 | 2014-08-25 | エクソゼミス,インコーポレイテッド | 好酸球ペルオキシダーゼ組成物およびその使用方法 |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5565197A (en) * | 1991-02-21 | 1996-10-15 | Exoxemis, Inc. | Method which utilizes a haloperoxidase composition to inhibit the growth of microorganisms which cause sexually transmitted diseases |
EP0693934B1 (en) * | 1993-04-15 | 2002-10-09 | ExOxEmis, Inc. | Methods and compositions for the prevention or treatment of sexually transmitted diseases |
NL9401048A (nl) * | 1994-03-31 | 1995-11-01 | Stichting Scheikundig Onderzoe | Haloperoxidasen. |
WO1995027009A1 (en) * | 1994-03-31 | 1995-10-12 | Stichting Scheikundig Onderzoek In Nederland | Antifouling paint containing haloperoxidases and method to determine halide concentrations |
DE4430327C1 (de) * | 1994-08-27 | 1996-05-09 | Degussa | Enzymatische, aktiven Sauerstoff liefernde Mischung sowie Verfahren zur enzymatischen Herstellung von Persäuren |
EP0857207A4 (en) * | 1995-10-25 | 2002-10-02 | Exoxemis Inc | MICROPOROUS COMPOSITION KILLING PATHOGENS |
JP2000512267A (ja) * | 1996-05-09 | 2000-09-19 | ノボ ノルディスク アクティーゼルスカブ | 抗微生物ペルオキシダーゼ組成物 |
EP0849585A3 (en) * | 1996-12-18 | 1998-09-02 | Kabushiki Kaisha Egawa | A microbe and cell function control device, a method of controlling the same, and a microbial ecology detector device |
EP1005362A4 (en) * | 1997-03-24 | 2002-10-09 | Clorox Co | CHLOROPEROXYDASE ENZYME SYSTEM FOR PRODUCING HYPOCHLOROUS ACID AND HYPOCHLORITE $ i (IN SITU) |
ID23661A (id) * | 1997-08-14 | 2000-05-11 | Novo Nordisk As | Komposisi antimixroba yang mengandung haloperoksidase sumber halida dan sumber amonium |
US6228128B1 (en) | 1997-11-10 | 2001-05-08 | Charlotte Johansen | Antimicrobial activity of laccases |
US6605751B1 (en) | 1997-11-14 | 2003-08-12 | Acrymed | Silver-containing compositions, devices and methods for making |
US7063970B1 (en) | 1999-05-06 | 2006-06-20 | Norozymes A/S | Enzymatic preservation of water based paints |
US8679523B2 (en) | 1999-12-30 | 2014-03-25 | Kimberly-Clark Worldwide, Inc. | Oxygen-delivery closed cell foam matrix for wound treatment |
CN1315523A (zh) * | 2000-03-28 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人过氧化酶18和编码这种多肽的多核苷酸 |
CN1315532A (zh) * | 2000-03-29 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人过氧化酶11和编码这种多肽的多核苷酸 |
AU2002220541A1 (en) * | 2000-12-15 | 2002-06-24 | Novozymes A/S | Use of haloperoxidase, peroxide and carboxylic acid |
US20040086453A1 (en) * | 2001-01-22 | 2004-05-06 | Howes Randolph M. | Compositions, methods, apparatuses, and systems for singlet oxygen delivery |
SE0200876L (sv) * | 2002-03-22 | 2003-09-23 | Krister Tano | Nässpray mot öroninflammationer |
EP1778010B1 (en) | 2004-07-30 | 2014-06-04 | Kimberly-Clark Worldwide, Inc. | Antimicrobial silver compositions |
US10251392B2 (en) | 2004-07-30 | 2019-04-09 | Avent, Inc. | Antimicrobial devices and compositions |
US8361553B2 (en) | 2004-07-30 | 2013-01-29 | Kimberly-Clark Worldwide, Inc. | Methods and compositions for metal nanoparticle treated surfaces |
WO2006034249A2 (en) | 2004-09-20 | 2006-03-30 | Acrymed, Inc. | Antimicrobial amorphous compositions |
US20070264355A1 (en) * | 2005-12-14 | 2007-11-15 | Binary, Llc | Binary compositions and methods for sterilization |
WO2007127236A2 (en) | 2006-04-28 | 2007-11-08 | Acrymed, Inc. | Antimicrobial site dressings |
WO2009116944A1 (en) * | 2008-03-20 | 2009-09-24 | Krister Tano | Use of a substance for manufacturing of a medicament for treatment of common cold |
EP2671449A1 (en) | 2012-06-06 | 2013-12-11 | Construction Research & Technology GmbH | Use of vanadium pentoxide particles as a biocide |
KR101434553B1 (ko) | 2012-09-04 | 2014-08-26 | 녹십자수의약품(주) | 어류의 스쿠티카충 및 병원성 세균 구제용 조성물 및 이들의 구제방법 |
US9814234B2 (en) | 2014-01-14 | 2017-11-14 | Exoxemis, Inc. | Bioactive heme-haloperoxidase compositions and methods of their use |
CN111713498B (zh) | 2014-04-30 | 2023-07-07 | 玛托克控股有限公司 | 抗微生物组合物 |
KR101647557B1 (ko) * | 2014-10-23 | 2016-08-10 | 동아대학교 산학협력단 | 과산화수소를 포함하는 푸자리움 푸지쿠로이의 선택배지 및 이의 용도 |
CA3022426C (en) | 2016-05-27 | 2023-05-16 | Exoxemis, Inc. | Myeloperoxidase compositions and methods for inhibition of lipopolysaccharides and lipid a |
DE102016120736A1 (de) | 2016-10-31 | 2018-05-03 | Johannes-Gutenberg-Universität Mainz | Biozider Stoff und damit hergestellte Produkte |
GB2566516A (en) | 2017-09-15 | 2019-03-20 | Univ Oxford Innovation Ltd | Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria |
GB201716986D0 (en) | 2017-10-16 | 2017-11-29 | Matoke Holdings Ltd | Antimicrobial compositions |
WO2020014493A1 (en) * | 2018-07-13 | 2020-01-16 | Allen Robert C | Haloperoxidase compositions and uses thereof |
GB2589863A (en) * | 2019-12-09 | 2021-06-16 | Institute Of Tech Sligo | Antimicrobial composition |
CN112259158B (zh) * | 2020-09-16 | 2023-03-28 | 青岛蔚蓝生物股份有限公司 | 一种在食品热处理加工过程中益生菌存活量的预测模型 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2679533A (en) | 1951-11-03 | 1954-05-25 | California Research Corp | Addition products of halogen and quaternary ammonium germicides and method for making the same |
GB2108387B (en) * | 1979-12-28 | 1984-03-21 | Green Cross Corp | A pharmaceutical composition containing myeloperoxidase |
US4473550A (en) * | 1981-01-16 | 1984-09-25 | Rosenbaum Robert S | Bactericidal compositions and methods |
US4473500A (en) * | 1981-05-12 | 1984-09-25 | Ciba-Geigy Corporation | Monoazo pigments derived from aminophthalimides and substituted acetoacetarylides or 2-hydroxy-3-naphthoylarylides |
JPS592686A (ja) * | 1982-06-25 | 1984-01-09 | Green Cross Corp:The | ミエロペルオキシダ−ゼの粉末製剤 |
US4588586A (en) * | 1983-01-03 | 1986-05-13 | Kessler Jack H | Method for disinfecting a contact lens |
US4516817A (en) * | 1983-04-25 | 1985-05-14 | Deters Paul M | Electrical jumper assembly |
US4576817A (en) * | 1984-06-07 | 1986-03-18 | Laclede Professional Products, Inc. | Enzymatic bandages and pads |
LU85479A1 (fr) * | 1984-07-25 | 1986-02-12 | Oleofina Sa | Compositions antibacteriennes de nourriture pour animaux et procede pour les preparer |
US4937072A (en) * | 1986-05-12 | 1990-06-26 | Kessler Jack H | In situ sporicidal disinfectant |
DK501686A (da) * | 1986-10-20 | 1988-04-21 | Otto Melchior Poulsen | Enzymholdigt, baktericidt middel samt tandplejemidler og saarbehandlingsmidler, som indeholder det |
US4996146A (en) | 1987-02-20 | 1991-02-26 | Kessler Jack H | Rapid sterilization enzymatic process with persistence |
FR2632525B1 (fr) | 1988-06-14 | 1992-07-31 | Improbio | Application therapeutique de la myeloperoxydase humaine |
WO1990003185A1 (en) * | 1988-09-28 | 1990-04-05 | Ideon Corporation | Combination enzyme immunotherapeutics |
FR2646777B1 (fr) * | 1989-05-12 | 1993-09-03 | Bio Serae Lab | Procede de preparation d'un produit particulaire antimicrobien, produit antimicrobien obtenu et applications |
GB9002422D0 (en) * | 1990-02-03 | 1990-04-04 | Boots Co Plc | Anti-microbial compositions |
-
1992
- 1992-02-14 JP JP50731092A patent/JP4063317B2/ja not_active Expired - Lifetime
- 1992-02-14 AU AU15364/92A patent/AU663869B2/en not_active Expired
- 1992-02-14 KR KR1019930702510A patent/KR930703012A/ko not_active Application Discontinuation
- 1992-02-14 WO PCT/US1992/001237 patent/WO1992014484A1/en active Search and Examination
- 1992-02-18 IL IL10099792A patent/IL100997A/en not_active IP Right Cessation
- 1992-02-18 IE IE051492A patent/IE920514A1/en not_active IP Right Cessation
- 1992-02-20 CA CA002061601A patent/CA2061601C/en not_active Expired - Lifetime
- 1992-02-21 DE DE69229512T patent/DE69229512T2/de not_active Revoked
- 1992-02-21 DE DE69233698T patent/DE69233698T2/de not_active Expired - Lifetime
- 1992-02-21 AT AT98122809T patent/ATE365048T1/de not_active IP Right Cessation
- 1992-02-21 EP EP98122809A patent/EP0923939B1/en not_active Expired - Lifetime
- 1992-02-21 AT AT92301448T patent/ATE181837T1/de not_active IP Right Cessation
- 1992-02-21 EP EP92301448A patent/EP0500387B1/en not_active Revoked
-
1994
- 1994-07-07 US US08/271,583 patent/US6294168B1/en not_active Expired - Lifetime
-
2004
- 2004-06-04 JP JP2004167857A patent/JP2004300157A/ja not_active Withdrawn
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007051153A (ja) * | 1995-06-01 | 2007-03-01 | Exoxemis Inc | 殺菌または滅菌のための酸素による活性化可能な処方物 |
JP2004537374A (ja) * | 2001-08-08 | 2004-12-16 | ノバルティス アクチエンゲゼルシャフト | コンタクトレンズ向けの消毒および洗浄システム |
JP2011519954A (ja) * | 2008-05-09 | 2011-07-14 | エクソゼミス,インコーポレイテッド | ミエロペルオキシダーゼの抗菌活性を増強するための組成物、およびそれらの使用方法 |
JP2014520853A (ja) * | 2011-07-11 | 2014-08-25 | エクソゼミス,インコーポレイテッド | 好酸球ペルオキシダーゼ組成物およびその使用方法 |
Also Published As
Publication number | Publication date |
---|---|
DE69233698T2 (de) | 2008-02-28 |
EP0923939A1 (en) | 1999-06-23 |
IL100997A0 (en) | 1992-11-15 |
ATE365048T1 (de) | 2007-07-15 |
US6294168B1 (en) | 2001-09-25 |
WO1992014484A1 (en) | 1992-09-03 |
CA2061601A1 (en) | 1992-08-22 |
KR930703012A (ko) | 1993-11-29 |
CA2061601C (en) | 2003-04-08 |
ATE181837T1 (de) | 1999-07-15 |
DE69233698D1 (de) | 2007-08-02 |
DE69229512T2 (de) | 2000-03-30 |
IL100997A (en) | 1996-09-12 |
IE920514A1 (en) | 1992-08-26 |
IE20000984A1 (en) | 2001-05-30 |
EP0500387A3 (en) | 1992-10-28 |
EP0500387B1 (en) | 1999-07-07 |
AU1536492A (en) | 1992-09-15 |
EP0500387A2 (en) | 1992-08-26 |
JP2004300157A (ja) | 2004-10-28 |
DE69229512D1 (de) | 1999-08-12 |
JP4063317B2 (ja) | 2008-03-19 |
AU663869B2 (en) | 1995-10-26 |
EP0923939B1 (en) | 2007-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06505482A (ja) | 感染治療および叢制御の方法および組成物 | |
CN103108643B (zh) | 包含过氧化物、醇和螯合剂的抗菌剂 | |
US5334383A (en) | Electrically hydrolyzed salines as in vivo microbicides for treatment of cardiomyopathy and multiple sclerosis | |
AU2017223689B2 (en) | Nitric oxide generating formulations and kits | |
JP2017519486A (ja) | アンモニア酸化Nitrosomonas eutropha株D23 | |
US5888505A (en) | Method for selectively inhibiting the growth of microbes using a haloperoxidase-halide-peroxide system | |
US12036239B2 (en) | Treatment of inflammatory bowel diseases through administration of enteric aerobization therapy | |
JP2011225593A (ja) | 心肺バイパス(cpb)手術の術後合併症を低減するための組成物 | |
Griffith et al. | Anti-microbiological and anti-infective activities of silver | |
CN105263489B (zh) | 抗微生物组合物及其制造方法 | |
CN118284405A (zh) | 肠有氧疗法 | |
WO2021202767A1 (en) | Enteric aerobization therapy | |
CN105916497A (zh) | 生物活性的亚铁血红素卤代过氧化物酶组合物及其使用方法 | |
Bolton et al. | Intraperitoneal povidone-iodine in experimental canine and murine peritonitis | |
IE85044B1 (en) | Haloperoxidase for the treatment of infection and control of flora | |
Maslov et al. | Effect of peroxidase on the development of experimental leprosy in mice after intraplantar infection | |
Wertheim et al. | Staphylococcus aureus nasal carriage: risks and prevention | |
Upadya et al. | Influence of bacterial interactions on the susceptibility to photodynamic inactivation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040604 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20040716 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20040826 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20040930 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050815 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050818 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060105 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061128 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071122 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071225 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110111 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110111 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120111 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130111 Year of fee payment: 5 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130111 Year of fee payment: 5 |